$LXRX News

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

Lexicon Pharmaceuticals (LXRX) As Phase 3 Enrollment Beats Plan Faces An Undervalued View

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

Lexicon Pharmaceuticals Completes Randomization Of Patients In Its Pivotal Phase 3 'Sotagliflozin In Patients With Symptomatic Obstructive And Non-Obstructive Hypertrophic Cardiomyopathy' Clinical Trial

Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally

Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?

How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Lexicon (LXRX) Q1 2026 Earnings Transcript

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade)

Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss